CDC recommends two doses of recombinant zoster vaccine (RZV, Shingrix) to prevent shingles and related complications in adults 50 years and older. Shingrix is also recommended for adults 19 years and older who have weakened immune systems because of disease or therapy.

Note: Zoster vaccine live (Zostavax) is no longer available for use in the United States, as of November 18, 2020.

What Everyone Should Know About the Shingles Vaccine
Information for Healthcare Professionals
Clinical Considerations for Use of RZV in Immunocompromised Adults
Related Pages